Tempero Bio develops treatments for Substance Use Disorders as a clinical-stage biopharmaceutical company.
Tempero Bio has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Tempero Bio's investors include Khosla Ventures, 8VC, Aditum Bio.
Tempero Bio is headquartered in Oakland, United States.
Tempero Bio develops treatments for Substance Use Disorders as a clinical-stage biopharmaceutical company.
Tempero Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tempero Bio — Funding & Investors." VCBacked, March 24, 2025, https://www.vcbacked.co/company/tempero-bio. Accessed July 19, 2026.
VCBacked. (2025). Tempero Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tempero-bio
{{cite web |title=Tempero Bio — Funding & Investors |url=https://www.vcbacked.co/company/tempero-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated